Get the Stockscreener App
27.65
0.90%
-0.25
Immunovant Inc stock is traded at $27.65, with a volume of 857.32K.
It is down -0.90% in the last 24 hours and down -24.56% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
See More
Previous Close:
$27.90
Open:
$28.03
24h Volume:
857.32K
Relative Volume:
0.57
Market Cap:
$5.71B
Revenue:
Net Income/Loss:
$-505.61M
P/E Ratio:
-9.983
EPS:
-2.7697
Net Cash Flow:
$-407.32M
1W Performance:
-8.63%
1M Performance:
-24.56%
6M Performance:
+0.80%
1Y Performance:
+54.21%
1-Day Range:
$27.55
$28.33
1-Week Range:
$27.83
$30.64
52-Week Range:
$16.77
$45.42
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-410-3120
Address
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
27.65 | 5.71B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
510.25 | 129.33B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.99 | 95.01B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.45 | 82.51B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.45 | 53.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.00 | 42.08B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Mkt Perform |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-14-25 | Initiated | Truist | Hold |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Immunovant chief legal officer Van Tuyl sells $42,543 in stock By Investing.com - Investing.com South Africa
Immunovant chief legal officer Van Tuyl sells $42,543 in stock By Investing.com - Investing.com Canada
Immunovant COO Melanie Gloria sells shares worth $71,846 By Investing.com - Investing.com South Africa
Form 4 Immunovant Inc For: 9 October By Investing.com - Investing.com South Africa
Form 4 Immunovant Inc For: 9 October - Investing.com India
Immunovant COO Melanie Gloria sells shares worth $71,846 - Investing.com India
Immunovant CEO Eric Venker sells $119,589 in shares By Investing.com - Investing.com Nigeria
Form 4 Immunovant Inc For: 5 October By Investing.com - Investing.com South Africa
Immunovant CEO Eric Venker sells $119,589 in shares By Investing.com - Investing.com Canada
Form 4 Immunovant Inc For: 5 October By Investing.com - Investing.com Canada
Form 4 Immunovant Inc For: 5 October By Investing.com - Investing.com UK
Immunovant CLO Christopher Van Tuyl Executes Mandatory Sale of 2,846 Shares for Tax Withholding - Kalkine Media
How (IMVT) Movements Inform Risk Allocation Models - Stock Traders Daily
Immunovant Announces Voting Outcomes from 2026 Annual Stockholders Meeting - Kalkine Media
Immunovant (IMVT) Slips 0.94% to $39.12 as Shares Test Resistance at $41.08OBV Breakout - vinanet.vn
Roivant Sciences (ROIV) president sells 200,000 shares under preset plan - Stock Titan
Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Roivant (NASDAQ: ROIV) president settles RSU taxes in shares - Stock Titan
Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says - marketscreener.com
Immunovant (IMVT) Watch: Stays Close to Unchanged at $44.37; Technical Setup: Support at $42.15 and Resistance at $46.59 Frame the Range at the CloseBear Flag - vinanet.vn
Immunovant (IMVT) Watch: Stays Close to Unchanged at $44.37; Technical Setup: Support at $42.15 and Resistance at $46.59 Frame the Range at the CloseStraddle Setup - dars.gov.et
Deep Track Capital, LP Trims Immunovant Inc (IMVT) Stake in Stra - GuruFocus
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *79wfgdDXy* - Villa de la Orotava
immunovant inc glp 1 receptor agonist diabetes weight managementView IiKNF3uia - Villa de la Orotava
Immunovant (IMVT) Results at a Glance: The Available Earnings Metric Delivers a Miss under the Current Snapshot; Post-Earnings: Shares Move Lower 1.98% in the Available RecordAnalyst Consensus Shift - vinanet.vn
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - Morningstar
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *BI2Y6DHdO* - scchr.jp
Investigation launched into Immunovant officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - PR Newswire
Immunovant (IMVT) Stock: Moves 1.49% Up to $44.96 in Latest Trading; Immediate View: Support at $42.71 and Resistance at $47.21 Frame the Range in the Latest ReadingPassive Flow - vinanet.vn
Immunovant (IMVT) Stock: Moves 1.49% Up to $44.96 in Latest Trading; Immediate View: Support at $42.71 and Resistance at $47.21 Frame the Range in the Latest ReadingSign of Strength - dars.gov.et
Immunovant (IMVT) Holds Steady at $41.82: Consolidation Between Key Support and ResistanceThematic ETF Flow - vinanet.vn
GSA Capital Partners LLP Takes $2.52 Million Position in Immunovant, Inc. $IMVT - MarketBeat
Assenagon Asset Management S.A. Has $639,000 Holdings in Immunovant, Inc. $IMVT - MarketBeat
Immunovant (IMVT) Holds Steady at $41.82 as Shares Consolidate in a Tight RangeGamma Exposure - vinanet.vn
Dimensional Fund Advisors LP Sells 103,356 Shares of Immunovant, Inc. $IMVT - MarketBeat
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st
Immunovant (IMVT) Q1 2027 Earnings Call Transcript - AOL.com
Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Australia
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com South Africa
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Nigeria
Immunovant stock hits 52-week high at 41.37 USD - Investing.com
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Canada
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com India
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com UK
The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT - marketbeat.com
Immunovant, Inc. (IMVT) Stock Analysis: Assessing the 21% Potential Upside with Strong Analyst Confidence - DirectorsTalk Interviews
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Van Tuyl Christopher | Chief Legal Officer |
Oct 07 '26 |
Sale |
32.06 |
1,327 |
42,544 |
175,218 |
| Gloria Melanie | Chief Operating Officer |
Oct 07 '26 |
Sale |
32.06 |
2,241 |
71,846 |
217,060 |
| Venker Eric | Chief Executive Officer |
Oct 02 '26 |
Sale |
34.11 |
3,506 |
119,590 |
257,075 |
| Venker Eric | Chief Executive Officer |
Oct 01 '26 |
Option Exercise |
14.46 |
92,187 |
1,333,024 |
346,467 |
| Van Tuyl Christopher | Chief Legal Officer |
Sep 23 '26 |
Sale |
36.36 |
2,846 |
103,481 |
176,545 |
| Pande Atul | Director |
Aug 28 '26 |
Sale |
43.27 |
1,500 |
64,905 |
116,731 |
| Pande Atul | Director |
Aug 28 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Gloria Melanie | Chief Operating Officer |
Aug 20 '26 |
Sale |
44.16 |
3,056 |
134,953 |
219,301 |
| Pande Atul | Director |
Jul 24 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Pande Atul | Director |
Jul 24 '26 |
Sale |
39.80 |
1,500 |
59,700 |
116,731 |
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):